SNPMiner Trials by Shray Alag


SNPMiner Trials: SNP Report


Report for SNP rs4604006

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Italian Multicentric Prospective Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib

Sorafenib represents the standard care for advanced hepatocellular carcinoma (HCC). However, molecular predictors of sorafenib efficacy have not yet been identified. The primary aim of the study is to validate the prognostic or predictive role of eNOS,Ang2, HIF-1, VEGF and VEGFR polymorphisms in relation to clinical outcome (progression-free survival, PFS) of HCC patients treated with sorafenib.

NCT02786342 Hepatocellular Carcinoma Procedure: blood sample collection
MeSH: Carcinoma, Hepatocellular
HPO: Hepatocellular carcinoma

At univariate analysis VEGF-A alleles C of rs25648, T of rs833061, C of rs699947, C of rs2010963, VEGF-C alleles T of rs4604006, G of rs664393, VEGFR-2 alleles C of rs2071559, C of rs2305948 were significant predictors of PFS and overall survival (OS).

At multivariate analysis rs2010963, rs4604006 and Barcelona Clinic Liver Cancer (BCLC) stage resulted to be independent factors influencing PFS and OS.

Primary Outcomes

Description: prognostic/predictive role of eNOS,Ang2, HIF-1, VEGF and VEGFR polymorphisms in relation to Progression Free Survival

Measure: PFS

Time: up to three years

Secondary Outcomes

Description: prognostic/predictive role of eNOS,Ang2, HIF-1, VEGF and VEGFR polymorphisms in relation to Overall Survival

Measure: OS

Time: up to three years


HPO Nodes


Hepatocellular carcinoma
Genes 54
PMS1 HFE KRAS MST1 FAH IL12A TGFBR2 MET IL12RB1 MSH6 RASGRP1 TCF4 BMPR1A SERPINA1 PMS2 MLH3 IGF2 IGF2R MMEL1 ATP7B SPIB PDGFRL PIK3CA GPR35 SLC25A13 JAG1 AHCY APC MLH1 TJP2 ABCB11 CASP8 HMBS POU2AF1 CASP10 PRKCD IRF5 RPS20 MSH2 SEMA4A CTNNB1 SPRTN UROD FAS FASLG EPCAM G6PC TNFSF15 SLC37A4 TNPO3 H19 TP53 AXIN1 FAN1